Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Advances in Drug Discovery of New Antitubercular Multidrug-Resistant Compounds

Full text
Author(s):
dos Santos Fernandes, Guilherme Felipe ; Chin, Chung Man ; Dos Santos, Jean Leandro
Total Authors: 3
Document type: Review article
Source: PHARMACEUTICALS; v. 10, n. 2 JUN 2017.
Web of Science Citations: 10
Abstract

Tuberculosis (TB), a disease caused mainly by the Mycobacterium tuberculosis (Mtb), is according to the World Health Organization (WHO) the infectious disease responsible for the highest number of deaths worldwide. The increased number of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, and the ineffectiveness of the current treatment against latent tuberculosis are challenges to be overcome in the coming years. The scenario of drug discovery becomes alarming when it is considered that the number of new drugs does not increase proportionally to the emergence of drug resistance. In this review, we will demonstrate the current advances in antitubercular drug discovery, focusing on the research of compounds with potent antituberculosis activity against MDR-TB strains. Herein, active compounds against MDR-TB with minimum inhibitory concentrations (MICs) less than 11 mu M and low toxicity published in the last 4 years in the databases PubMed, Web of Science and Scopus will be presented and discussed. (AU)

FAPESP's process: 16/09502-7 - Design, synthesis and antitubercular activity of new oxazolidinones useful for the treatment of multidrug-resistant tuberculosis
Grantee:Guilherme Felipe dos Santos Fernandes
Support type: Scholarships in Brazil - Doctorate